Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.75, Implies 7% Upside
Analyst estimates compiled by FactSet show Myriad Genetics’ average 12-month price target cut to $5.75 from $6.14. The range is $4 to $10 per share, implying about 7% upside versus the Jul. 30 close. Consensus remains “Hold” with 2 Buys, 5 Holds, and 2 Sells.
How this was made
The 30-second read
Why it matters
A lower average target implies analysts are marking down expected value, but the unchanged Hold consensus suggests expectations are not shifting to a strong sell case.
Market read
This is a consensus estimate update rather than a new fundamental disclosure, so it is more relevant for positioning than for a fresh thesis.
What to watch
The article does not state the rationale for the target change, so traders should verify whether any specific driver (guidance, trial, reimbursement, or balance-sheet risk) actually changed.
Background
The piece summarizes FactSet-derived analyst consensus price targets and ratings for Myriad Genetics.
Ticker impact
Myriad Genetics’ consensus average price target fell from $6.14 to $5.75, with a Hold rating still dominant among covering analysts.
Likely limited immediate price impact unless traders treat the target cut as a broader earnings-risk signal.
The only disclosed change is the analyst price target average and unchanged Hold consensus; no new company-specific fundamental catalyst is provided.
Market effects
Minimal, since this is a single-name analyst target update without sector-wide new information.
None indicated.
None indicated.
Counterpoint
A Hold consensus with a wide target range ($4 to $10) suggests dispersion; the average cut may not reflect a clear deterioration in fundamentals.
Key entities
- equity issuerMyriad Genetics, Inc.
Subject of the article, with consensus price target cut and Hold rating maintained.
